Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Diagnosis takes years because early disease mimics eczema.
No cure without transplant.
Quality of life with itch and visible disease is under-measured in trials.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
CHMP negative opinion on Kinselby (resminostat) for advanced mycosis fungoides and Sézary syndrome
Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy
Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.
A milestone in how this cancer is treated.
Topical treatment of mycosis fungoides-type CTCL (Ledaga)